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Abstract	23	
Background:	Despite	increases	in	diagnostics	and	effective	treatments,	over	300	000	men	die	from	24	
prostate	cancer	highlighting	the	need	for	specific	and	differentiating	biomarkers.	AR	phosphorylation	25	
associates	with	castrate-resistance,	with	pARser213	promoting	transcriptional	activity.	We	hypothesise	26	
that	 combined	 pARser81	 and	 pARser213	 reduces	 survival	 and	 would	 benefit	 from	 dual-targeting	27	
androgen-dependent	and	Akt-driven	disease.			28	
Methods:	 Immunohistochemistry	 and	 immunofluorescence	was	 performed	on	matched	hormone-29	
naïve	and	castrate-resistant	prostate	cancer	samples.	TempO-Seq	gene	profiling	was	analysed	using	30	
DESeq2	package.	LNCaP-AI	cells	were	stimulated	with	DHT	or	EGF.	WST-1	assays	were	performed	to	31	
determine	effects	of	Enzalutamide	and	BKM120	on	cell	viability.		32	
Results:	Following	the	development	of	castrate-resistance,	pARser81	expression	reduced	and	pARser213	33	
expression	 increased.	 Castrate-resistance	 pARser81	 expression	was	 not	 associated	with	 survival	 but	34	
high	pARser213	expression	was	associated	with	reduced	survival	from	relapse.	Combined	high	pARser81	35	
and	pARser213	was	associated	with	reduced	survival	from	relapse.	pARser81	expression	was	induced	by	36	
10nM	 DHT	 or	 10nM	 EGF	 and	 pARser213	 expression	 was	 induced	 by	 treatment	 with	 10nM	 EGF	 in	37	
LNCaP-AI	 cells.	 Cell	 viability	was	 reduced	 following	 treatment	with	 10nM	Enzalutamide	 and	10nM	38	
BKM120.	 8	 genes	 were	 differentially	 expressed	 between	 hormone-naïve	 and	 castrate-resistant	39	
tumours	and	25	genes	were	differentially	expressed	between	castrate-resistant	 tumours	with	high	40	
and	low	pARser213	expression.		41	
Conclusion:	 Combined	 pARser81	 and	 pARser213	 provides	 a	 novel	 prognostic	 biomarker	 for	 castrate-42	
resistant	 disease	 and	 a	 potential	 predictive	 and	 therapeutic	 target	 for	 prostate	 cancer.	 Further	43	
studies	will	be	required	to	investigate	the	combined	effects	of	targeting	AR	and	PI3K/AKT	signaling.	44	
45	
	45	
Introduction	46	
Prostate	 cancer	 (CaP)	 accounts	 for	 over	 47	 000	 new	 UK	 diagnoses	 each	 year	 (1).	 The	47	
androgen	 receptor	 (AR)	 plays	 vital	 roles	 in	 CaP;	 therefore,	 current	 therapies	 aim	 to	 inhibit	 AR	48	
activation	 directly	 or	 indirectly	 by	 depleting	 androgens	 via	 androgen	 deprivation	 therapy	 (ADT).	49	
Despite	a	90%	success	rate,	almost	all	locally	advanced	and	metastatic	patients	relapse	within	24-36	50	
months	and	develop	castrate-resistant	prostate	cancer	(CRPC).	Loss	of	responsiveness	to	hormonal	51	
therapies	is	the	main	challenge	facing	CaP	management	(2).		52	
AR	 phosphorylation,	 including	 serine	 81	 and	 308	 are	 linked	 to	 AR	 nuclear-cytoplasmic	53	
shuttling	and	CaP	progression	(3).		Serine	81	is	the	most	common	AR	phosphorylated	site	(pARser81)	54	
and	 associates	 with	 AR	 transcriptional	 activity.	 In	 the	 presence	 of	 androgens,	 pARser81	 occurs	 by	55	
cyclin-dependent	 kinases	 (CDKs),	 such	 as	 CDK1	 and	 9,	which	 sensitize	 AR	 to	 low	 levels	 of	 adrenal	56	
androgens	(4).		However,	in	the	absence	of	androgens,	pARser81	may	occur	by	alternative	kinases	and	57	
reactivate	AR	signalling.	58	
Recently,	 androgen-independent	 AR	 activation	 has	 been	 proposed	 as	 a	 mechanism	 for	59	
castrate-resistance.	 Phosphatidylinositol	 3-OH	 kinase	 (PI3K)/Akt	 signaling	 associates	 with	60	
phosphorylated	 AR	 serine	 213	 (pARser213),	 resulting	 in	 AR	 stability	 (5).	 We	 have	 previously	61	
demonstrated	 in	 vitro	 upregulation	 of	 PI3K/Akt	 signalling	 at	 castrate-resistance	 and	 increased	62	
pARser213	 expression.	 Furthermore,	 we	 demonstrated	 an	 increase	 in	 pARser213	 expression	 in	 the	63	
transition	 from	 hormone-naïve	 to	 CRPC,	 this	 increase	 was	 also	 associated	 with	 decreased	 cancer	64	
specific	 survival	 from	relapse	 (6).	However,	no	mechanistic	analysis	or	analysis	of	differential	gene	65	
expression	 profiles	 were	 conducted	 for	 the	 differing	 roles	 of	 AR	 phosphorylation	 at	 the	 different	66	
sites.		67	
Epidermal	growth	factor	receptor	(EGFR)	associates	with	PI3K/Akt	activation	and	CRPC.	We	68	
previously	 reported	 that	 EGFR	 variant	 III	 (EGFRvIII),	 a	 constitutively	 activated	 form	 of	 EGFR,	69	
associates	with	 CRPC.	 EGFRvIII	 activates	 PI3K/Akt	 signalling,	with	 EGFRvIII	 and	 loss	 of	 PTEN	 being	70	
prevalent	 in	 CaP,	 suggesting	 an	 androgen-independent	 mechanism	 for	 pARser81	 and	 pARser213	71	
expression	 (6,	 7).	 However,	 despite	 no	 causative	 relationship	 observed	 between	 EGFRvIII	 and	72	
pARser81,	 EGFRvIII	 expression	 reduces	 CDK	 inhibitors	 and	 activates	 the	 cell	 cycle.	 As	 pARser81	73	
expression	 is	 mediated	 by	 CDKs,	 it	 is	 hypothesized	 that	 EGFRvIII	 activates	 CDK	 expression	 and	74	
increases	pARser81,	however	this	remains	to	be	identified.		A	Phase	II	clinical	trial	combined	the	anti-75	
androgen,	Enzalutamide,	with	the	PI3K-inhibitor,	BKM120,	to	target	both	pathways	simultaneously.	76	
However,	PSA	was	only	 reduced	 in	23%	of	patients	and	adverse	effects	occurred.	Armstrong	et	al	77	
concluded	more	predictive	biomarkers	would	improve	study	outcome	(8).		78	
Therefore,	 this	 study	 aimed	 to	 determine	 the	 use	 of	 pARser81	 and	 pARser213	 as	 prognostic	79	
biomarkers	and	whether	 these	 sites	 could	be	exploited	as	dual	 therapeutic	 targets	 and	utilised	as	80	
predictive	biomarkers	for	CRPC.	Furthermore,	by	defining	genes	associated	with	AR	phosphorylation	81	
status	future	pathway	analysis	could	identify	novel	and	precise	targets	for	these	patients.		82	
83	
Materials	and	Methods	83	
Cell	Culture	84	
LNCaP-androgen-independent	((LNCaP-AI)	grow	in	the	absence	of	androgens)	cells	were	gifted	from	85	
Professor	 Craig	 Robson	 (University	 of	 Newcastle)	 and	 maintained	 in	 phenol	 red	 RMPI	 1640	86	
supplemented	with	10%	charcoal-treated	foetal	calf	serum.	Media	was	supplemented	with	penicillin,	87	
streptomycin,	and	L-Glutamine	(Life	Technologies,	UK).		88	
Antibody	Specificity		89	
Antibody	specificity	for	pARser81	and	pARser213	was	previously	confirmed	(6,	9).	 In	brief,	Willder	et	al	90	
performed	 peptide	 competitive	 assays	 to	 confirm	 the	 specificity	 of	 pARser81	 phosphorylation	 site	91	
using	the	peptide	with	the	protein	sequence	QQQQQQET(pS)PRQQ	raised	in	a	rabbit	(EZbiolab	Inc,	92	
USA)	at	1:1	and	incubated	with	the	pARser81	antibody	(#07-1375;	Merk	Millipore,	USA)	overnight	at	4°	93	
before	 performing	 immunohistochemistry	 as	 below.	 Additionally,	McCall	et	 al	 performed	western	94	
blots	 for	 pARser213	 (#IMG-561;	 Imgenex,	 USA)	 (also	 termed	 pARser210)	 to	 determine	 antibody	95	
specificity.	 This	 was	 followed	 by	 confirming	 that	 the	 pARser213	 antibody	 only	 detected	 the	96	
phosphorylated	 protein	 by	 destroying	 phosphorylated	 proteins	 with	 calf	 intestinal	 alkaline	97	
phosphatase.	 One	 treated	 slide	 plus	 one	 untreated	 slide	 was	 stained	 with	 pARser213	 using	98	
immunohistochemistry	as	below.		99	
Time	course	drug	treatment	100	
LNCaP-AI	cells	were	stimulated	and/	or	inhibited	by	10nM	DHT,	10nM	EGF,	10nM	Enzalutamide	and/	101	
or	10nM	BKM120	over	1	and	12	hours.		102	
Immunofluorescence	103	
Immunofluorescence	 was	 performed	 as	 described	 (10).	 pARser81	 and	 pARser213	 antibodies	 were	104	
incubated	overnight	at	4°C	at	1:1000	and	1:200	respectively	and	visualised	using	the	Zeiss	LSM	780	105	
Confocal	 (Zeiss,	Germany).	 	 Pixel	 intensity	was	 quantified	 using	 ImageJ,	with	 10	 images	 taken	per	106	
experiment	 performed	 to	 n=3	 and	 statistical	 analysis	 was	 performed	 using	 one-way	 ANOVA	with	107	
Bonferroni	correction	and	Dunnett’s	test.	108	
WST	Proliferation	Assay		109	
WST-1	proliferation	assays	(Roche	Diagnostics,	Germany)	were	performed	on	LNCaP-AI	cells	to	n=3	110	
according	to	manufacturer’s	 instructions.	Statistical	analysis	was	performed	using	one-way	ANOVA	111	
with	Bonferroni	correction	and	Dunnett’s	test.	112	
Patients	113	
In	 total,	 109	 patients	with	matched	 hormone-naïve	 (HN)	 and	 castrate-resistant	 (CR)	 tumour	 pairs	114	
were	included	within	this	study	(diagnosed	between	1984-2000	with	locally	advanced	or	metastatic	115	
CaP	from	Greater	Glasgow	and	Clyde	Health	Board).	Ethical	approval	was	acquired	from	Multicentre	116	
Research	Ethics	Committee	for	Scotland	(MREC/01/0/36)	and	Local	Research	and	Ethics	Committees.	117	
Patients	 were	 selected	 based	 on	 their	 response	 to	 hormone	 treatment	 (sub-capsular	 bilateral	118	
orchidectomy	 or	 LHRH	 agonists	 combined	 with	 antiandrogens)	 and	 their	 relapse	 (2	 rises	 in	 PSA	119	
>10%).	 HN	 tissue	 was	 obtained	 via	 trans-rectal	 ultrasound	 guided	 biopsies	 and	 CR	 tissue	 was	120	
obtained	by	 transurethral	 resection	of	 the	prostate	 (TURP)	as	a	 result	of	 relieving	bladder	outflow	121	
obstruction.			122	
Immunohistochemistry		123	
Immunohistochemistry	for	pARser81	and	pARser213	was	performed	as	described	(6,	9,	11,	12).	pARser81	124	
(#07-1375;	Merk	Millipore,	USA)	antibody	was	 incubated	overnight	 at	4°C,	 at	1:4000	and	pARser213	125	
(#IMG-561;	 Imgenex,	 USA)	 was	 incubated	 for	 1	 hour	 at	 room	 temperature	 at	 1:100.	 A	 negative	126	
control	was	included	with	the	absence	of	the	primary	antibody.	Slides	were	scanned	and	visualised	127	
using	Hamamatsu	NanoZoomer	(Welwyn	Garden	City,	UK)	and	Slidepath	Digital	Image	Hub,	version	128	
4.0.1	 (Leica	 Biosystems,	 UK).	 Tissue	 staining	 intensity	 was	 scored	 by	 two	 independent	 observers	129	
using	the	weighted	histoscore	method	to	assess	staining	 intensity	and	the	percentage	of	cells	with	130	
weak,	moderate,	and	strong	intensity	(13).	In	brief,	the	score	was	calculated	by	sum	of	(1	X	%	cells	131	
staining	weakly	positive)	+	(2	X	%	cells	staining	moderately	positive)	+	(3	X	%	cells	staining	strongly	132	
positive)	 with	 a	 maximum	 of	 300	 (100%	 strongly	 stained)	 and	 a	 minimum	 of	 0	 (100%	 with	 no	133	
staining).	134	
Immunofluorescence	on	Patient	Tissue		135	
Immunofluorescence	was	performed	as	follows:	sections	were	dewaxed	in	histoclear	and	rehydrated	136	
through	graded	alcohol.	Antigen	retrieval	was	performed	in	pH9	Tris-EDTA	buffer	(5mM	Trizma	Base,	137	
1mM	EDTA)	 under	 pressure	 for	 5	minutes.	 pARser81	 (#07-1375;	Merk	Millipore,	 USA)	 and	 pARser213	138	
(#IMG-561;	 Imgenex,	 USA)	 antibodies	were	 incubated	 together	 overnight	 at	 4°C,	 diluted	 at	 1:100	139	
and	1:600	respectively.	Staining	was	captured	using	the	Zeiss	LSM	780	Confocal,	visualised	using	Carl	140	
Zeiss	 ZEN	 2	 blue	 edition	 software	 (Zeiss,	 Germany),	 and	 categorised	 based	 on	 absence	 and/	 or	141	
presence	of	phosphorylated	AR	antibodies.		142	
Statistical	Analysis		143	
Statistical	 analysis	was	performed	using	 SPSS	 version	22.	 Interclass	 correlation	 coefficients	 (ICCCs)	144	
confirmed	 weighted	 histoscores	 were	 consistent	 between	 2	 independent	 observers.	 Receiver	145	
operator	 characteristic	 (ROC)	 curves	 identify	 threshold	 for	 low/high	 expression.	 	 Combined	146	
expression	 of	 pARser81	 and	 pARser213	 was	 coded	 as;	 low	 pARser81	 and	 pARser213	 the	 both	 low	 group,	147	
either	high	pARser81	or	pARser213	the	one	high	group,	and	both	high	pARser81	and	pARser213	the	both	high	148	
group.	Time	to	biochemical	relapse	(BR),	cancer-specific	survival	from	diagnosis	(CSSD)	and	relapse	149	
(CSSR)	was	analysed	using	Kaplan	Meier	 log-rank	analysis	 followed	by	Cox	 regression,	Chi-squared	150	
analysis,	and	Wilcoxon	signed-rank	test.			151	
TempO-Seq	Gene	Differential	Expression	152	
TempO-Seq	 gene	 expression	 profiling	 was	 performed	 according	 to	 manufacturer’s	 directions	 (17	153	
matched	 tumour	pairs	 and	an	additional	 6	CRPC	 tumours)	 and	 the	 Surrogate+Tox	panel	was	used	154	
comprising	of	2723	genes	(BioSpyder	Technologies	Inc.,	USA)	(14,	15).	Data	was	analysed	using	the	155	
DESeq2	package	to	compare	differentially	expressed	genes	between	HN	and	CR	tumours	pairs	and	156	
AR	phosphorylation	status.	Fold	change	(FC)	and	p-values	were	calculated	statistically	and	adjusted	157	
for	multiple	comparisons	with	p-value<0.05	considered	statistically	significant.	When	comparing	AR	158	
phosphorylation	 status,	 due	 to	 lack	 of	 number	 an	 unadjusted	 p-value<0.001	 was	 considered	159	
statistically	significant.		160	
161	
	161	
Results	162	
Patient	characteristics	163	
Clinico-pathological	 data	was	 collected	 from	 109	 patients	 with	matched	 hormone-naïve	 (HN)	 and	164	
castrate-resistant	 (CR)	 tumour	 pairs	 and	 included	 age	 at	 diagnosis	 (mean	 69,	 Interquartile	 Range	165	
(IQR)	66-74),	Gleason	grade	at	diagnosis	(mean	7,	IQR	6-9),	Gleason	grade	at	relapse	(mean	8.55,	IQR	166	
8-9),	 serum	PSA	concentration	at	diagnosis	 (mean	146.51	ng/ml,	 IQR	8.55-126.18),	and	serum	PSA	167	
concentration	at	 relapse	 (mean	62.95	ng/ml,	 IQR	4.57-39.50).	All	patients	had	biochemical	 relapse	168	
with	 a	 mean	 time	 to	 relapse	 from	 diagnosis	 of	 3.24	 years	 (IQR	 1.58-4.50).	 Mean	 cancer	 specific	169	
survival	from	relapse	(CSSR)	was	2.7	years	(IQR	1.1-3.5	years)	and	mean	cancer	specific	survival	(CSS)	170	
was	5.7	years	(IQR	3.4-7.2	years)	(Supplementary	Table	1).	171	
AR	phosphorylation	expression	following	the	transition	from	hormone-naïve	to	castrate-resistant	172	
disease		173	
HN	nuclear	pARser81	expression	ranged	from	0-250	weighted	histoscore	units	(WHU)	with	a	median	of	174	
100	WHU	(interquartile	range	(IQR)	50-135).	ROC	curve	analysis	determined	a	threshold	of	115	WHU	175	
that	 separated	 pARser81	 expression	 into	 high	 and	 low.	HN	pARser81	 expression	 at	 diagnosis	was	 not	176	
associated	 with	 time	 to	 biochemical	 relapse,	 CSS	 (p=0.630	 and	 p=0.933	 respectively)	 or	 clinico-177	
pathological	 features.	 Following	 the	 development	 of	 CR	 disease,	 pARser81	 expression	 decreased	178	
(p=0.002)	(Figure	1A	and	B).	CR	nuclear	pARser81	expression	ranged	from	0-200	WHU	with	a	median	179	
of	 90	WHU	 ((IQR	 50-120).	 ROC	 curve	 analysis	 determined	 a	 threshold	 of	 95	WHU	 that	 separated	180	
pARser81	 expression	 into	 high	 and	 low.	 Despite	 this,	 46.7%	 of	 CR	 samples	 expressed	 high	 pARser81	181	
expression.	 However,	 CR	 pARser81	 expression	 was	 not	 associated	 with	 CSSR	 (p=0.068)	 (Figure	 1C).	182	
Furthermore,	HN	nuclear	 pARser213	 expression	 ranged	 from	0-175	WHU	with	 a	median	 of	 11	WHU	183	
(IQR	0-80).	ROC	curve	analysis	determined	a	threshold	of	9	WHU	that	separated	pARser213	expression	184	
into	high	and	low.	HN	pARser213	expression	was	not	associated	with	time	to	biochemical	relapse,	CSS	185	
(p=0.150	and	p=0.861	respectively)	or	clinico-pathological	 features.	CR	nuclear	pARser213	expression	186	
ranged	from	0-200	WHU	with	a	median	of	90	WHU	((IQR	40-160).	ROC	curve	analysis	determined	a	187	
threshold	of	93	WHU	that	separated	pARser213	expression	into	high	and	low.	CR	pARser213	expression	188	
increased	 in	 66.3%	 of	 patients	 (p=0.002),	 with	 high	 expression	 associating	 with	 reduced	 CSSR	189	
(p=0.001,	HR=2.457	(1.388-4.349))	(Figure	1D,	E,	and	F).	High	CR	pARser213	expression	stratified	mean	190	
CSSR	from	4.44	years	 in	 low	expressing	tumours	to	2.54	years	 in	high	expressing	tumours	and	was	191	
independent	 in	 cox	 regression	 multivariate	 analysis	 when	 compared	 with	 clinico-pathological	192	
features	(p=0.029,	HR=2.618).	5-year	survival	was	reduced	from	35%	for	patients	with	low	pARser213	193	
expression	to	16%	for	patients	with	high	expression.		194	
Combined	castrate-resistant	pARser81	and	pARser213	expression	score	195	
High	 CR	 pARser81	 and	 high	 pARser213	 expression	 reduced	 CSSR	 from	 5.73	 years	 to	 2.03	 years	196	
(p=000297)	(Figure	2A).	Furthermore,	5-year	survival	was	reduced	from	47%	for	patients	expressing	197	
low	of	both	 sites	 to	7%	 for	patients	expressing	high	of	both	 sites.	 Following	 immunofluorescence,	198	
21.7%	of	CR	tumours	expressed	both	pARser81	and	pARser213	within	the	same	cell.	CSSR	was	reduced	199	
from	5.26	years	to	1.69	years	with	5-year	survival	reducing	from	40%	to	22%	(p=0.000011)	(Figure	2B	200	
and	C).		201	
Stimulating	and	inhibiting	AR	phosphorylation	in	vitro	202	
In	LNCaP-AI	cells,	androgen-dependent	stimulation	by	10nM	DHT	induced	pARser81	expression	by	30	203	
minutes	and	8	hours	(p<0.001)	(Figure	3A	C,	E	and	F),	however	only	a	slight	increase	in	pARser213	was	204	
observed	(Figure	3B,	D,	E	and	F).	Androgen-independent	stimulation	by	10nM	EGF	induced	pARser81	205	
expression	by	5	minutes	and	2	hours	(Figure	4A,	C,	E	and	F)	and	pARser213	expression	by	30	minutes	206	
and	 4	 hours	 (p<0.001	 and	 p<0.001	 respectively)	 (Figure	 4B,	 D,	 E	 and	 F).	 	 Subsequently,	 we	207	
determined	 the	 effects	 on	 AR	 phosphorylation	 by	 blocking	 androgen-dependent	 by	 the	 non-208	
steroidal	second-generation	AR	antagonist	Enzalutamide	or	PI3K-driven	phosphorylation	by	the	pan-209	
class	PI3K	 inhibitor	BKM120.	10nM	Enzalutamide	significantly	 reduced	10nM	DHT	 induced	pARser81	210	
expression	and	interestingly	reduced	pARser213	expression	to	unstimulated	levels	(Figure	5A,	B	and	C).	211	
Additionally,	 10nM	 BKM120	 significantly	 reduced	 10nM	 EGF	 induced	 pARser81	 and	 pARser213	212	
expression	 (Figure	 5D,	 E	 and	 F).	 Unfortunately,	 when	 used	 as	 monotherapies,	 neither	 10nM	213	
Enzalutamide	 nor	 10nM	 BKM120	 was	 able	 to	 reduce	 cell	 viability	 by	 10	 days	 (Figure	 5G	 and	 H).	214	
However,	LNCaP-AI	cell	viability	was	significantly	 reduced	after	10	days	 following	combining	10nM	215	
Enzalutamide	and	10nM	BKM120	when	compared	to	cells	cultured	in	full	media	(p<0.05)	(Figure	5i).		216	
Differentially	expressed	genes	between	high	and	low	castrate-resistant	AR	phosphorylation	status	217	
Differential	 gene	 expression	 analysis	 on	 2723	 genes,	 pre-selected	 for	 their	 biological	 relevance	 in	218	
cancer,	was	performed	on	10	patients	with	matched	HN	and	CR	tumour	samples.	In	CR	tumours,	8	219	
genes	 were	 differentially	 expressed	 (DE)	 when	 compared	 to	 their	 matched	 HN	 tumour	 including	220	
KIF11,	 HIST1H3B,	 UGT1A10,	 TYMS,	 and	 CDKN3	 (adjusted	 p-value<0.005)	 (Supplementary	 table	 2).	221	
Furthermore,	expression	analysis	was	performed	between	high	and	 low	AR	phosphorylation	status	222	
at	CR.	However,	sample	numbers	in	each	group	were	low	with	no	genes	DE	following	correction	for	223	
multiple	testing	(CR	pARser81:	high	n=5	and	low=12,	CR	pARser213:	high	n=7	and	low	n=13).		Therefore,	224	
we	reduced	the	threshold	for	unadjusted	p-values	for	significance	to	p<0.001.	At	CR,	tumours	with	225	
high	 pARser213	 expression	 had	 25	 genes	 DE	 including	 18	 downregulated	 and	 7	 upregulated	 when	226	
compare	to	low	pARser213	expressing	CR	tumours	(p<0.001).	DE	genes	with	the	lowest	p-values	were	227	
GSTP1,	CAMK2B,	ATF5,	UQCRFS1,	 and	C1R.	The	 top	3	upregulated	genes	with	 the	 largest	absolute	228	
log2foldchange	 are	 implicated	 in	 CaP	 including	 CAMK2B	 (p=6.44x10-5,	 log2FC=2.367,	 lfcSE=0.605)	229	
involved	 in	 aldosterone	 synthesis,	 HPN	 (TMPRSS1)	 (p=0.00035,	 log2FC=1.938,	 lfcSE=0.542)	 which	230	
promotes	CaP	metastasis,	and	AMACR	(p=0.00045,	log2FC=2.213,	lfcSE=0.631)	which	is	expressed	in	231	
CaP	(Supplementary	table	3).	However,	MAOA	(p=0.00117,	log2FC=-2.073,	lfcSE=0.639),	involved	in	232	
epithelial	 to	 mesenchymal	 transition,	 was	 the	 only	 one	 gene	 DE	 in	 high	 versus	 low	 CR	 pARser81	233	
expression	 suggesting	 elevated	 CR	 pARser213	 expression	 might	 have	 a	 stronger	 effect	 on	 AR	234	
transcription	than	CR	pARser81.		235	
236	
	236	
Discussion	237	
Despite	 the	 development	 of	 new	 hormonal	 therapies	 to	 treat	 advanced	 CaP,	 such	 as	238	
Abiraterone	(Johnson	&	Johnson)	and	MDV3100	(Medivation),	in	the	majority	of	advanced	CaPs	only	239	
temporary	disease	control	 is	achieved	with	androgen-independent	 reactivation	of	AR	commencing	240	
2-3	 years	 after	 ADT.	 Therefore,	 this	 traditional	 etiology	 of	 androgen-driven	 disease	 needs	 to	 be	241	
revised	 and	 the	 elucidation	 of	 molecular	 mechanisms	 involved	 in	 CRPC	 is	 required.	 It	 has	 been	242	
hypothesised	 that	 various	 pathways	 lead	 to	 CaP	 recurrence	 in	 hormone-deprived	 environments.	243	
However,	 with	 the	 lack	 of	 predictive	 markers	 to	 identify	 activated	 pathways,	 inappropriate	244	
treatments	 are	 administered,	 clinical	 trials	 fail,	 and	 patient	 survival	 is	 not	 improving	 despite	245	
increases	in	new	therapeutic	options.		246	
PI3K	 activation	 due	 to	 the	 loss	 of	 the	 tumor	 suppressor	 gene,	 PTEN,	 highlights	 a	 genetic	247	
abnormality	that	induces	androgen-independent	AR	expression	in	40-70%	of	patients	(16,	17)	.	Akt,	a	248	
downstream	member	 of	 PI3K,	 plays	 vital	 roles	 in	 cancer	 growth	 and	migration	 and	 increases	 AR	249	
transcriptional	activity	 in	 vitro	 identifying	pARser213	 in	 response	 to	Akt	binding	 (18).	 Interestingly,	 it	250	
has	previously	been	identified	that	high	pARser213	expression	in	this	cohort	is	associated	with	elevated	251	
pAKTser473	at	castrate-resistance	(6).	An	additional	link	between	Akt	activity	and	survival	during	ADT	252	
has	 been	 identified,	 therefore	 promoting	 CRPC	 development	 (19).	 Furthermore,	 AR	 nuclear	253	
exportation	 is	 influenced	by	pARser650	by	MAPK	 signalling,	 therefore	highlighting	 contributions	 that	254	
signal-transduction	 cascades	 play	 in	 CaP	 (4).	 However,	 in	 vitro	 studies	 using	 Akt	 specific	 and	 PI3K	255	
specific	 inhibitors	 show	 differing	 results	 with	 both	 reduced	 and	 increased	 AR	 expression	 being	256	
reported	 (20).	 	 Therefore,	 this	 study	 compared	 a	 marker	 of	 traditional	 androgen-dependent	257	
activation	(pARser81)	with	a	controversial	marker	of	androgen-independent	activation	(pARser213)	and	258	
determined	their	utility	as	individual	and	combined	biomarkers.	259	
In	this	cohort,	following	the	development	of	CR	disease,	8	genes	were	DE	when	compared	to	260	
their	 matched	 HN	 tumour	 with	 the	majority	 involved	 in	 the	 cell	 cycle	 including	 CDK1	 (M-phase),	261	
CDKN3	 (cell-cycle	 regulator),	 TYMS	 (S-phase),	 and	 HMMR	 (mitotic	 spindle	 integrity)	 (21-24).	262	
Interestingly,	upregulated	CDK1	in	CR	tumours	is	linked	to	enhancing	CR	AR	and	pARser81	expression	263	
in	response	to	low	androgen	levels	(25).	Subsequently,	in	Figure	1	we	observed	46.7%	of	CR	tumours	264	
with	an	elevation	in	pARser81	expression	and	a	reduced	in	CSSR.	In	LNCaP-AI	cells,	we	induced	pARser81	265	
expression	 by	 10nM	 DHT	 and	 subsequently	 inhibited	 expression	 following	 10nM	 Enzalutamide	266	
treatment.	However,	no	effect	of	cell	viability	was	observed.		267	
High	 CR	 pARser213	 expression	 associated	 with	 reduced	 CSSR	 by	 1.9	 years	 (p=0.001)	 and	268	
suggests	that	following	ADT	the	AR	is	reactivated	androgen-independently.	However,	contradictory	269	
to	our	findings	of	decreased	survival,	it	has	been	reported	that	pARser213	in	response	to	Akt	can	lead	270	
to	 ligand	 dissociation	 and	 degradation	 of	 AR	 (26).	 Furthermore,	 pARser213	 in	 response	 to	 Mdm2	271	
results	 in	 ubiquitination	 and	 degradation	 of	 AR	 and	 its	 splice	 variant	 AR-V7	 (27).	 Following	272	
transcriptomic	analysis,	multiple	genes	were	dysregulated	 in	high	CR	pARser213	expressing	 tumours.	273	
However,	 due	 to	 lack	 of	 numbers	 unadjusted	 p-values	 were	 assessed	 due	 to	 their	 biological	274	
relevance.	HPN,	which	codes	for	hepsin,	 is	overexpressed	 in	up	to	90%	of	CaPs	often	>10-fold	(28,	275	
29).	We	observed	almost	a	2-fold	increase	in	HPN	in	high	CR	pARser213	expressing	tumours	and	not	in	276	
high	 pARser81	 expressing	 tumours.	 Furthermore,	HPN	 correlates	with	 high	Gleason	 grade	 and	 poor	277	
clinical	 outcome	 (30,	 31).	 Additionally,	 GSTP1	 was	 underrepresented	 in	 high	 pARser213	 expressing	278	
tumours,	 a	 gene	 involved	 in	 reducing	 oxidative	 damage.	 However,	 when	 silenced	 GSTP1	 can	279	
promote	CaP	initiation	in	90-95%	of	CaPs	suggesting	pARser213	represents	an	aggressive	phenotype.		280	
ErbB	 family	 receptors	 are	 involved	 in	 CaP	 tumourigenesis	 and	 progression,	 with	 aberrant	281	
associations	 observed	 during	 the	 development	 of	 CR	 disease	 and	 loss	 of	 androgen	 signaling	 (3).	282	
HER2	 overexpression	 has	 been	 reported	 in	 CaP	 progression	 much	 like	 breast	 cancer,	 another	283	
hormone	sensitive/refractory	disease	(32).	HER2	inhibitors	have	shown	to	reduce	recurrence	by	up	284	
to	50%	 in	HER2	positive	breast	cancers,	with	 the	hope	of	HER	specific	 inhibitors	similarly	 reducing	285	
CaP	 progression	 (33,	 34).	 However,	 overexpression	 of	 EGFR	 is	 not	 associated	 with	 CaP	 initiation,	286	
differentiation,	 or	 positive	 margins	 but	 with	 progression	 and	 castrate-resistance	 (35-37).	287	
Interestingly,	 as	 a	 result	 of	 EGFRvIII	 expression	 and	 subsequent	 activation	 of	 PI3K/Akt,	 increased	288	
proliferation	and	cell	cycle	progression	has	been	observed.	This	signalling	reduces	the	levels	of	the	289	
cyclin-dependent	 kinase	 inhibitor,	 p27KIP1,	 a	 known	 inhibitor	 of	 the	 transition	 from	G1	 to	 S	 phase	290	
within	the	cell	cycle	in	glioblastoma	(38).	Interestingly,	EGFRvIII	associates	with	reduced	expression	291	
of	 CDK	 inhibitors	 and	 is	 hypothesised	 to	 result	 in	 elevated	 CDK	 expression	 and	 ultimately	292	
overexpression	of	pARser81.	Following	10nM	EGF	stimulation,	we	observed	a	significant	 induction	of	293	
pARser81	an	pARser213	expression,	further	adding	to	weight	to	a	potential	mechanism	in	which	pARser81	294	
expression	 reactivates	 AR	 in	 CR	 CaP.	 Additionally,	 when	 LNCaP-AI	 cells	 were	 treated	 with	 10nM	295	
BKM120,	a	significant	reduction	in	EGF	induced	pARser81	and	pARser213	expression	was	observed.	296	
Due	to	the	promiscuity	of	AR	activation,	we	have	hypothesized	that	AR	activation	at	multiple	297	
sites	would	have	a	cumulative	prognostic	effect.	When	patients	expressed	both	pARser81	and	pARser213	298	
at	 relapse	 they	 had	 a	 reduced	 CSSR	 of	 3.71	 years	 (p=0.000297).	 This	 significantly	 increased	 the	299	
prognostic	power	of	these	markers	when	compared	alone	to	patient	survival	(pARser81	p=0.068,	and	300	
pARser213	p=0.001).	 Furthermore,	patients	expressing	pARser81	 and	pARser213	within	 the	 same	cell	 via	301	
immunofluorescence	resulted	in	a	reduced	CSSR	of	3.57	years	(p=0.00011).	302	
Due	 to	 a	 feedback	 loop	 observed	 between	 AR	 and	 PI3K/AKT	 cascade,	 the	 use	 of	 anti-303	
androgens	and	PI3K	inhibitors	as	monotherapies	have	lacked	efficacy	with	no	significant	reduction	in	304	
cell	viability	observed	 in	LNCaP-AI	cells	 following	10nM	Enzalutamide	or	10nM	BKM120	(Figure	5G	305	
and	H).	 However,	when	 targeting	 both	 androgen-depenedent	 and	 PI3K-driven	AR	 activation	 using	306	
10nM	 enzalutamide	 and	 10nM	 BKM120,	 cell	 viability	 signifincatly	 reduced	 in	 LNCaO-AI	 cells.	307	
Therefore,	we	have	hypothesise	that	patients	expressing	pARser81	and	pARser213	expression	within	the	308	
same	cell	would	benefit	from	this	dual	therpauetic	approach	and	improve	the	efficacy	of	the	clinical	309	
trial	 by	Armstrong	et	al	 (8).	However,	 LNCaP	AI	 cells	harbour	multiple	mutations	 including	T878A,	310	
F876L,	and	F877L	within	the	ligand	binding	domain	portion	of	the	AR,	resulting	in	a	broader	ligand-311	
binding	 domain	 pocket	 which	 could	 lead	 to	 AR	 activation	 by	 other	 stimuli	 such	 as	 estrogen	 and	312	
potential	agonistic	effects	following	anti-androgen	treatment	(39-41).	Therefore,	the	effects	seen	in	313	
LNCaP	AI	cells	in	response	to	stimulation	and/	inhibition	may	only	represent	a	subgroup	of	prostate	314	
cancers	with	such	mutations	and	needs	to	be	performed	in	further	models	to	validate	results.		315	
To	 conclude,	 further	 elucidation	 of	 these	 biomarkers	 are	 required	 to	 determine	 their	316	
localisation/co-localisation	 and	 whether	 combining	 pARser81	 and	 pARser213	 will	 provide	 any	 further	317	
understanding	 and/	 or	 prognostic	 power.	 In	 addition,	 the	 use	 of	 various	 drug	 combinations	 with	318	
anti-androgens	 such	as	Enzaultamide	and	PI3K/Akt	 inhibitors	 such	BKM120	on	patients	depending	319	
on	 their	 AR	 phosphorylation	 status	 will	 be	 further	 explored	 to	 determine	 correct	 timing	 and	320	
treatment	stratergies	for	patients	that	may	benefit	from	early	intervention.	321	
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Tables	and	Figures	438	
Figure	1:	Androgen	receptor	phosphorylation	status	between	hormone-naïve	and	castrate-resistant	439	
prostate	 cancer.	 (A)	 High	 and	 low	 pARser81	 expression	 in	 prostate	 cancer	 (B)	 pARser81	 expression	440	
significantly	 reduces	 following	 the	 development	 of	 castrate-resistant	 disease	 (C)	 High	 pARser81	441	
expression	 does	 not	 significantly	 reduce	 cancer	 specific	 survival	 from	 relapse	 (D)	 High	 and	 low	442	
pARser213	 expression	 in	 prostate	 cancer	 (E)	 pARser213	 expression	 significantly	 increases	 following	 the	443	
development	of	castrate-resistant	disease	(F)	High	pARser213	 	expression	significantly	reduced	cancer	444	
specific	survival	from	relapse.	Wilcoxon	signed-rank	tests	and	Kaplan	Meier	survival	curves	with	log-445	
rank	 tests	 were	 considered	 significant	 if	 P<0.05.	 Censor	 lines	 were	 included	 to	 indicate	 loss	 of	446	
patient	follow	up.	447	
	448	
	449	
Figure	 2:	 Combined	 pARser81	 and	 pARser213	 expression	 in	 castrate-resistant	 tumours.	 (A)	 Following	450	
immunohistochemistry,	 castrate-resistant	 patients	with	 high	 pARser81	 and	 high	 pARser213	 expression	451	
had	 significantly	 reduced	 cancer	 specific	 survival	 from	 relapse	 (B)	 Following	 dual	452	
immunofluorescence,	 castrate-resistant	 patients	 expressing	 pARser81	 and	 pARser213	 within	 the	 same	453	
cell	had	a	significantly	reduced	cancer	specific	survival	from	relapse	(C)	Example	of	castrate-resistant	454	
tumours	expressing	only	pARser81,	only	pARser213,	and	combined	pARser81	an	pARser213	within	the	same	455	
cell.	Kaplan	Meier	 survival	 curves	with	 log-rank	 tests	were	considered	significant	 if	P<0.05.	Censor	456	
lines	 were	 included	 to	 indicate	 loss	 of	 patient	 follow	 up.	 Blue	 fluorescence	 DAPI	 was	 used	 as	 a	457	
nuclear	counterstain.	Scale	bar	represents	20µm.	458	
459	
	460	
Figure	3:	Stimulating	androgen-dependent	androgen	receptor	signalling	in	LNCaP-AI	cells.	(A	and	B)	461	
Exposure	to	10	nM	DHT	over	1	hour	significantly	increased	pARser81	expression	by	30	minutes	but	not	462	
pARser213	expression	(C	and	D)	Exposure	to	10	nM	DHT	over	12	hours	significantly	increased	pARser81	463	
expression	by	 8	 hours	 but	 not	 pARser213	 expression	 (E	 and	 F)	Quantification	of	AR	phosphorylation	464	
pixel	 intensity	 following	1	and	12	hour	10	nM	DHT	stimulation.	 	Each	experiment	was	repeated	to	465	
N=3.	DAPI	was	included	as	a	nuclear	stain	and	scale	bars	represent	50	µm.	Fluorescence	expression	466	
was	 quantified	 and	 compared	 to	 a	 control	 containing	 no	 primary	 antibody.	 Error	 bars	 represent	467	
standard	 error	 and	 statistical	 analysis	 was	 performed	 using	 a	 one-way	 ANOVA	 with	 Bonferroni	468	
correction	and	Dunnett’s	test.	**	indicate	a	significant	difference	of	P<0.001.	469	
	470	
471	
	471	
Figure	4:	Stimulating	androgen-independent	androgen	receptor	signalling	in	LNCaP-AI	cells.	(A	and	B)	472	
Exposure	 to	 10	 nM	 EGF	 over	 1	 hour	 significantly	 increased	 pARser81	 expression	 by	 5	minutes	 and	473	
pARser213	 expression	 by	 30	minutes	 (C	 and	 D)	 Exposure	 to	 10	 nM	 EGF	 over	 12	 hours	 significantly	474	
increased	pARser81	expression	by	2	hours	and	pARser213	expression	by	4	hours	(E	and	F)	Quantification	475	
of	 AR	 phosphorylation	 pixel	 intensity	 following	 1	 and	 12	 hour	 10	 nM	 EGF	 stimulation.	 	 Each	476	
experiment	was	repeated	to	N=3.	DAPI	was	included	as	a	nuclear	stain	and	scale	bars	represent	50	477	
µm.	 Fluorescence	 expression	 was	 quantified	 and	 compared	 to	 a	 control	 containing	 no	 primary	478	
antibody.	Error	bars	represent	standard	error	and	statistical	analysis	was	performed	using	a	one-way	479	
ANOVA	 with	 Bonferroni	 correction	 and	 Dunnett’s	 test.	 **	 indicate	 a	 significant	 difference	 of	480	
P<0.001.	481	
	482	
483	
	483	
Figure	5: Inhibiting	androgen	receptor	signalling	in	LNCaP-AI	cells.	(A,B	and	C)	10	nM	Enzalutamide	484	
treatment	significantly	reduced	10	nM	DHT	induced	pARser81	expression	but	not	pARser213	expression	485	
(D,	E	and	F)	10	nM	BKM120	treatment	significantly	reduced	10	nM	EGF	induced	pARser81	and	pARser213	486	
expression	 (G)	 No	 effect	 on	 LNCaP-AI	 cell	 viability	 was	 observed	 following	 10	 nM	 Enzalutamide	487	
treatment	 over	 10	 days	 (H)	 No	 effect	 on	 LNCaP-AI	 cell	 viability	 was	 observed	 following	 10	 nM	488	
BKM120	 treatment	 over	 10	 days	 (I)	 Combined	 treatment	 with	 10	 nM	 Enzalutamide	 and	 10	 nM	489	
BKM120	significantly	reduced	LNCaP-AI	cell	viability	by	10	days.	 	Each	experiment	was	repeated	to	490	
N=3.	DAPI	was	included	as	a	nuclear	stain	and	scale	bars	represent	50	µm.	Fluorescence	expression	491	
was	 quantified	 and	 compared	 to	 a	 control	 containing	 no	 primary	 antibody.	 Error	 bars	 represent	492	
standard	 error	 and	 statistical	 analysis	 was	 performed	 using	 a	 one-way	 ANOVA	 with	 Bonferroni	493	
correction	 and	 Dunnett’s	 test.	 *	 and	 **	 indicate	 a	 significant	 difference	 of	 P<0.05	 and	 P<0.001	494	
respectively.	495	
	496	
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Supplementary	 table	 1:	 Clinico-pathological	 cohort	 characteristics	 and	 relationship	 with	 clinical	498	
outcome	measures.	The	number	of	patients	in	each	group	are	described	along	with	the	significance	499	
to	time	to	biochemical	relapse	(BR),	cancer	specific	survival	from	relapse	(CSSR),	and	cancer	specific	500	
survival	(CSS).	Kaplan	Meier	survival	curves	with	log-rank	tests	were	considered	significant	if	P<0.05.	501	
Clinico-pathological	
characteristics	
Patient	Numbers	n	(%)		
Total	n	=	109	
Clinical	Outcome	Significance	
Age	at	Diagnosis		
(≤70/>70	years/	Missing)	
61	(35%)/	46	(26%)/	68	(39%)	 CSS:	P=0.246	
BR:P=0.210	
Gleason	Grade	at	Diagnosis	
(<7/	7/	>7/	Missing)	
27	(15%),	24	(14%),	49	(28%),	
75	(43%)	
CSS:	P=0.001	
BR:	P=0.031	
Serum	PSA	Concentration	at	
Diagnosis	
(<10/	10-20/	>20/	Missing)	
26	(15%),	11	(6%),	61	(35%),	
77	(44%)	
CSS:	P=0.380	
BR:	P=0.058	
Metastases	at	Diagnosis		
(No/	Yes/	Missing)	
68	(39%),	30	(17%),	77	(44%)	 CSS:	P=0.000077	
BR:	P=0.007	
Gleason	Grade	at	Relapse	
(<7/	7/	>7/	Missing)	
5	(3%),	12	(7%),	84	(48%),	74	
(42%)	
CSSR:P=0.675	
Serum	PSA	Concentration	at	
Relapse		
(<10/	10-20/	>20/	Missing)	
24	(14%),	6	(3%),	28	(16%),	
117	(67%)	
CSSR:	P=0.023	
Metastases	at	Relapse		
(No/	Yes/	Missing)	
20	(11%),	56	(32%),	99	(57%)	 CSSR:	P=0.000442	
502	
	502	
Supplementary	table	2:	Differential	gene	expression	analysis	between	hormone-naïve	and	castrate-503	
resistant	prostate	cancer.	8	gene	were	significantly	upregulated	in	castrate-resistant	tumours	when	504	
compared	to	their	matched	hormone-naive	tumour.	P>0.05	was	considered	significant	for	adjusted	505	
p-values.	506	
Gene	 Log2FoldChange	 lfcSE	 P-Value	 Adjusted	P-Value	
KIF11_3588	 1.606687	 0.324044	 7.11E-07	 0.002094	
HIST1H3B_12576	1.717355	 0.391572	 1.16E-05	 0.017011	
UGT1A10_28864	2.229366	 0.539585	 3.60E-05	 0.022069	
TYMS_21327	 1.304365	 0.318614	 4.24E-05	 0.022069	
CDKN3_17690	 1.660734	 0.406628	 4.42E-05	 0.022069	
CDK1_1196	 2.053808	 0.503347	 4.50E-05	 0.022069	
HMMR_3040	 1.194755	 0.300411	 6.98E-05	 0.029344	
CENPW_1256	 1.040229	 0.268995	 0.00011	 0.04053	
507	
	507	
Supplementary	 table	 3:	 Differential	 gene	 expression	 analysis	 between	 high	 and	 low	 pARser213	508	
expression	 in	 castrate-resistant	 tumours.	 25	 genes	 were	 differentially	 expressed	 in	 high	 pARser213	509	
expressing	 castrate-resistant	 tumours	 when	 compared	 to	 low	 pARser213.	 18	 genes	 were	510	
downregulated	and	7	genes	were	upregulated.	P>0.001	was	considered	significant	for	unadjusted	p-511	
values.	512	
Gene	 Log2foldchange	 LfcSE	 P-Value	 Adjusted	P-Value	
GSTP1_24644	 -2.3134	 0.578919	 6.44E-05	 0.04741	
CAMK2B_26957	 2.36701	 0.60481	 9.09E-05	 0.04741	
ATF5_501	 1.34956	 0.346107	 9.65E-05	 0.04741	
UQCRFS1_7566	 0.86679	 0.23363	 0.00021	 0.06063	
C1R_871	 -1.3565	 0.369807	 0.00024	 0.06063	
CASP1_26966	 -1.384	 0.38356	 0.00031	 0.06063	
HPN_25853	 1.93783	 0.541716	 0.00035	 0.06063	
KRT15_19413	 -3.248	 0.910927	 0.00036	 0.06063	
ARHGAP8_26848	 1.34436	 0.37758	 0.00037	 0.06063	
AMACR_14170	 2.21333	 0.630683	 0.00045	 0.0662	
LOC100510495_28176	-1.3128	 0.379924	 0.00055	 0.06728	
MYLK_4414	 -1.9181	 0.555136	 0.00055	 0.06728	
C3_886	 -1.9042	 0.554412	 0.00059	 0.06728	
SMAD3_27880	 -0.9936	 0.292956	 0.0007	 0.06982	
ID1_14943	 -1.8632	 0.550338	 0.00071	 0.06982	
IGFBP6_26498	 -1.8047	 0.542909	 0.00089	 0.07082	
CFH_27007	 -1.4165	 0.426346	 0.00089	 0.07082	
FGF2_2405	 -1.661	 0.500727	 0.00091	 0.07082	
CCND1_1062	 -0.7696	 0.232679	 0.00094	 0.07082	
HPN_3091	 1.86637	 0.565271	 0.00096	 0.07082	
SCARB1_6117	 1.08261	 0.333161	 0.00116	 0.08114	
FLNA_25912	 -1.4413	 0.448573	 0.00131	 0.0817	
BMP4_737	 -1.2925	 0.403309	 0.00135	 0.0817	
ZEB2_23804	 -1.1773	 0.367524	 0.00136	 0.0817	
TPSB2_17547	 -1.5698	 0.490942	 0.00139	 0.0817	
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